Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells $235,535.82 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 871 shares of BeOne Medicines stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $270.42, for a total value of $235,535.82. Following the transaction, the senior vice president owned 160 shares of the company’s stock, valued at $43,267.20. The trade was a 84.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total value of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total value of $103,447.88.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $264.48 on Friday. The business’s 50 day moving average price is $299.42 and its two-hundred day moving average price is $314.63. The company has a market cap of $29.02 billion, a PE ratio of 59.17 and a beta of 0.49. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors have recently made changes to their positions in ONC. EFG International AG bought a new stake in shares of BeOne Medicines during the fourth quarter worth approximately $25,000. Leonteq Securities AG bought a new stake in shares of BeOne Medicines during the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines during the second quarter worth approximately $35,000. CWM LLC boosted its holdings in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the period. Finally, Group One Trading LLC bought a new stake in shares of BeOne Medicines during the fourth quarter worth approximately $61,000. Institutional investors own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

ONC has been the topic of a number of recent analyst reports. Leerink Partners boosted their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and lowered their price target for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Truist Financial reissued a “buy” rating and set a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Wolfe Research assumed coverage on BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.